We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMQP.
RNS Number : 9747D
Quantum Pharma PLC
03 May 2017
Quantum Pharma Plc ('Quantum' or 'the Group')
Final audited results for the year ended 31 January 2017 ('the year')
3 May 2017
For immediate release
Financial highlights
-- Revenue increased by 28% to GBP88.8m (2016: GBP69.2m). -- Gross profit remained flat at GBP25.9m (2016: GBP25.9m). -- Adjusted EBITDA(1) of GBP10.1m (2016: GBP12.5m) with profitability run-rate increasing.
-- Statutory operating loss of GBP9.8m (2016: GBP7.5m profit) resulting from the decisive and one-off actions highlighted in the January trading update to simplify and focus the business.
-- Net debt(1) reduced by almost half to GBP13.0m (2016: GBP24.6m).
Key developments
-- Transition to a more focused and simplified business strategy led by a new Board.
-- Group repositioned with a leaner operating structure and balance sheet aligned to simplified strategy.
-- Secured renewal of long-term exclusive contracts to supply unlicensed medicines to three of the largest wholesale and pharmacy chains in the UK.
-- Successfully launched a number of new products during the year and post year-end, including key unlicensed-to-licensed ('UL2L') product Glycopyrronium Bromide Oral Solution.
-- Simplified product portfolio performing well and refocused pipeline progressing to plan.
-- Successful placing in November 2016, raising GBP15.0m (before expenses) to significantly reduce net debt.
Hot Features
Premium
-- Closure of loss-making business NuPharm Laboratories Limited ('NuPharm').
Ian Johnson, Non-executive Chairman of Quantum, said: "This year's results draw a line under the past performance of the Group. They mark the transition to a more focused and simplified business led by a new Board, and demonstrate real progress in executing our strategy. The Board is confident in the future prospects of the Group and we look forward to reporting on further strategic progress as we move forward."
Chris Rigg, CEO of Quantum, said: "I am very pleased with the progress we have made to date. We have driven a step change in the profitability of the Niche Pharmaceuticals division in the second half by focusing on launching and commercialising products where we have a competitive advantage. In addition, the Group has cemented its position as the UK's market-leading specials business by renewing exclusive contracts with three of the four main wholesale and pharmacy chains in the UK. Operating costs across the Group have been reduced and our net debt position at the year-end was lower than expected at GBP13.0m. We exited the financial year with a much improved profitability run-rate that is supportive of market expectations for the current financial year and we are well-placed to deliver future growth by focusing on our core Niche and Specials businesses."
An analyst briefing will be held at 09:30am today, at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN. A copy of the final results presentation given by Chris Rigg (Chief Executive Officer) and Gerard Murray (Chief Financial Officer) will be released later this morning on Wednesday 3 May 2017 on the Group's website http://ir.quantumpharmagroup.com/content/investor/presentations.asp. (1) For a list of definitions of non-GAAP measures and references to reconciliations to GAAP measures turn to page 13.
This announcement contains inside information for
the purposes of Article 7 of
EU Regulation 596/2014.
For further information
Quantum Pharma Plc Tel: +44 (0) 1207 279 404
Ian Johnson, Non-executive www.quantumpharmaplc.com
Chairman
Chris Rigg, Chief Executive
Officer
Gerard Murray, Chief Financial
Officer
ir@quantumpharma.co.uk
Tel: +44 (0) 20 7496 3000
N+1 Singer
(Nominated Advisor & Broker)
Sandy Fraser / Nick Owen
/ James White
Tel: +44 (0) 20 7466 5000
Media enquiries: www.buchanan.uk.com
Buchanan
Henry Harrison-Topham
/ Sophie Cowles
quantumpharma@buchanan.uk.com
Notes to editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital and homecare markets. Quantum Pharma Plc operates through three divisions - Specials, Niche Pharmaceuticals and Medication Adherence - offering a portfolio of innovative and complementary products and services.
For further information, please visit www.quantumpharmagroup.com.
As a result of rounding throughout this announcement it is possible that tables may not cast and change percentages may not calculate precisely.
Chief Executive's review
I am pleased to report that the Group has made excellent progress in implementing its more focused and simplified strategy and that our performance in the second half of the year was very encouraging. The impact of the actions taken to confront the challenges we have faced leave the Group with a clean balance sheet and a leaner operating structure on which we intend to build and grow. The Group's profitability run-rate has been materially improved and we are now well-placed to take advantage of existing and future opportunities within our core businesses.
The Specials division ('Specials') remains profitable and cash generative, providing a strong platform for our development programme that is predominantly focused on unlicensed-to-licensed ('UL2L') products. The trading performance of the Niche Pharmaceuticals division ('Niche') has been transformed by the successful launch of a number of products during the year and post year-end, including our largest product to date Glycopyrronium Bromide Oral Solution 1mg/5ml ('Glyco'), and the elimination of on-going losses, unnecessary costs and marginal activities. In addition, the drive to grow our network of commercial partnerships is showing clear signs of progress. Our focus on the two core pillars of Specials and Niche will continue to drive performance improvement.
The long-term fit of the Medication Adherence ('MA') division within the Group, particularly given its low gross margin contribution, is under review.
A focused and simplified strategy
Following the conclusion of a strategic review performed during the year, we have refocused and simplified the business to:
-- Closely align our business model to the UK prescribing hierarchy by moving products from an unlicensed-to-licensed status.
-- Maintain market-leading position in the specials market whilst we progress the development and licensing of products in our pipeline where we have a competitive advantage.
-- Invest in our UL2L development programme to license key unlicensed specials so that we can protect and grow our market share and secure economies of scale.
-- Broaden our network of commercial partnerships to secure multiple routes to market for our product portfolio.
UL2L prioritisation
Prioritising our UL2L product developments delivered through Niche, emphasising those products where we can be first to market, is a key part of our strategy. This type of development plays to our strengths, with less time and investment needed to penetrate the market and achieve scale.
Having simplified the product portfolio to prioritise development of the Group's top specials licensing opportunities, it currently comprises 57 products. 19 of these products have been launched or out-licensed in the UK, with 12 having been commercialised post-simplification. The overall performance of these products since simplification has been very good, with the benefits of portfolio rationalisation evident. A further 3 products have been licensed in the UK and are in the process of being commercialised. There are an additional 35 products in various phases of development, of which 25 are UL2L developments. All developments are currently progressing to timetable. Going forward we will provide updates with respect to our licensed product portfolio as part of our interim and final results communications.
In order to release investment capacity to support UL2L prioritisation we have cancelled all development programmes where we cannot identify a commercial partnership and do not believe we can commercialise the opportunity ourselves. As a consequence, GBP7.2m of balance sheet investment in these products has been impaired, which is a key constituent of the reported statutory operating loss.
Broadening our commercial partnerships
Our non-UL2L portfolio is comprised of niche generic products where, although we will not have first-mover advantage and significant sales and marketing capability will likely be required to market them, we believe there remains a market opportunity.
Past experience tells us that taking share from incumbent competitors can be very challenging without an existing sales and marketing capability, and that converting these non-UL2L opportunities takes time and significant investment unless there is an established market presence.
We have therefore taken steps to commercialise selected non-UL2L products in our portfolio by partnering with other businesses that have more experience of taking generic products to market, which will help us to commercialise these developments to their fullest potential and accelerate our access to revenues through revenue-sharing agreements. We are progressing partnerships to support this strategy.
International opportunities
Our product pipeline holds significant value potential. In the UK market, the Group is well-established due to its existing infrastructure and commercial relationships built through our market-leading Specials division. We also have extensive experience and understanding of the UK's development and regulatory approval process as governed by the MHRA through the activities of our Niche division. Our strategic position in the UK is therefore strong.
We are currently seeking to realise the potential of our product portfolio beyond the UK and extend our reach into other geographies by broadening our network of international commercial partnerships. These partnerships will seek to emphasise both export and localised manufacture together with distribution opportunities to secure market access without the need to establish our own local presence.
Consolidating our position in the specials market
Our Specials division continues to perform robustly and reliably, and is cash generative. This resilient performance is particularly encouraging given the increasing competitiveness and regulatory pressure within the specials market. We have cemented our market-leading position by agreeing new long-term exclusive supply contracts with three of the largest UK wholesale and pharmacy chains, being AAH Pharmaceuticals Limited, Bestway Panacea Healthcare Limited, trading as Well Pharmacy, and Phoenix Healthcare Distribution Limited. Quantum Pharmaceutical Limited, a business within the Specials division, is the UK market leader in the supply of unlicensed medicines and around 89% of its volumes are under exclusive contracts.
Our attention is now turning to driving operational efficiencies and improvements in the Specials division to underpin profitability and provide us with the commercial agility necessary to react to market dynamics.
NuPharm closure
Following a period of sustained trading losses, the Board took the decision in October 2016 to commence consultation on the closure of NuPharm. Trading ceased at NuPharm in January 2017 in line with our stated intention and it was placed into administration on 26 April 2017 following an orderly closure process.
The total loss incurred on the closure of NuPharm is GBP13.7m, which reflects trading losses and closure costs of GBP1.7m, and GBP12.0m of written down balance sheet investment. This loss is shown as a discontinued operation in the consolidated income statement as NuPharm's activities as a contract manufacturer are considered to be a separate major line of business. The cash impact of NuPharm's trading losses and closure costs during the year was GBP2.4m.
Summary and outlook
I am very pleased with the progress we have made to date. We have driven a step change in the profitability of the Niche Pharmaceuticals division in the second half by focusing on launching and commercialising products where we have a competitive advantage. In addition, the Group has cemented its position as the UK's market-leading specials business by renewing exclusive contracts with three of the four main wholesale and pharmacy chains in the UK. Operating costs across the Group have been reduced and our net debt position at the year-end was lower than expected at GBP13.0m. We exited the financial year with a much improved profitability run-rate that is supportive of market expectations for the current financial year and we are well-placed to deliver future growth by focusing on our core Niche and Specials businesses.
Divisional Review
Niche Pharmaceuticals division ('Niche')
The financial year ended 31 January 2017 has been a pivotal year for the Niche division following the launch of a number of new products, the most significant of which has been Glycopyrronium Bromide Oral Solution 1mg/5ml ('Glyco'), and substantial operational changes to focus and simplify the business in line with our strategy.
Revenue grew 35% during the year to GBP5.8m (2016: GBP4.3m), driven primarily by the contribution from Glyco following its launch in August 2016. Adjusted EBITDA contracted by 33% to GBP1.4m (2016: GBP2.1m) with Glyco's trading contribution offset by a reduction in out-licensing income of GBP0.5m and an increased operating cost base that has now been addressed.
The adjusted EBITDA monthly run-rate of Colonis, the commercialisation arm of the Niche division, has been transformed during the second half of the year. During the first half of the year Colonis had invested ahead of meaningful sales activity to support the launch of a number of products in the portfolio where we needed engagement with healthcare professionals.
Following the decision to prioritise UL2L developments a number of underperforming product lines were discontinued, including the Mucodis range and Ergocalciferol 50,000 IU. This decision has allowed the division to focus investment on what it believes are the right products and stop on-going investment in the discontinued products, yielding significant savings. Colonis therefore exited the year with a positive monthly adjusted EBITDA run-rate, underpinned by strong contributions from Glyco alongside a number of other launched products, and a lower cost base.
In addition to Glyco, we launched several other products during the second half of the year and just after the year-end, which are delivering in line with management expectations. These include:
-- Aviticol(TM) and Colecalciferol capsules (licensed for the treatment and prevention of Vitamin D deficiency) in an 800 IU strength in July 2016 and 1000 IU strength in August 2016;
-- Metformin Oral Solution (licensed for the treatment of type 2 diabetes) in 500mg/5ml, 850mg/5ml and 1000mg/5ml strengths in December 2016;
-- Folic Acid 1mg/1ml Oral Solution (licensed for the treatment of folate deficiency) and Acetylcysteine Sachets 200mg (licensed as a mucolytic) during February and March post year-end; and
-- Levothyroxine Oral Solution (indicated for hyperthyroidism) in 25mcg/5ml, 50mcg/5ml and 100mcg/5ml strengths launched in April 2017.
Lamda, the product development and licensing arm of the Niche division, delivered another good performance. The development pipeline is now fully integrated at Lamda, absorbing around 60% of Lamda's total development capacity this year. The business has also continued to generate strong development, supply and royalty revenue from a range of third-party projects.
Specials division ('Specials')
The Specials division delivered another solid performance during the year, generating 89% of the Group's adjusted EBITDA before Group costs. The division provides a strong platform for our product development and licensing activities, as well as valuable insights into trends within the specials market that we use to inform our new product development decisions.
Revenue increased by 7% to GBP57.6m (2016: GBP53.6m) and adjusted EBITDA contracted by 6% to GBP10.1m (2016: GBP10.7m). Sales order volumes in Quantum Pharmaceutical Limited ('QPL') increased by 6%, supported by volumes gained as a result of the acquisition of 281 Sainsbury's stores by Lloyds Pharmacy in September. This was partly offset by the impact of our licensing of Glyco in August 2016, which cannibalised some existing specials sales.
The drive to secure efficiency savings across the NHS continues to create pricing pressures and changes to prescribing trends in favour of more cost-effective medicines. We are seeing this most notably through a gradual shift towards prescription of tariff medicines in place of clinically equivalent but sometimes more expensive non-tariff alternatives. This has been a feature of the industry for a number of years and we are continuing to manage this dynamic through a variety of initiatives, including margin improvement through the manufacture of more products in-house as opposed to external sourcing.
QPL was also successful in retaining all major key accounts during the year, including securing a five-year exclusive supply relationship with our largest customer, AAH Pharmaceuticals Limited, which supplies over 1,800 Lloyds Pharmacy stores and 8,000 independents across the UK. Post the year-end we entered into long-term exclusive supply agreements with Bestway Panacea Healthcare Limited, trading as Well Pharmacy, and Phoenix Healthcare Distribution Limited, who supply Rowlands pharmacies, for two and three years respectively. Securing these agreements mean we supply three out of the four largest national pharmacy chains in the UK on an exclusive basis, satisfying all of their unlicensed medicine and special obtain demand. Around 89% of our specials and special obtains sales volumes in QPL are sourced from customers with whom we have an exclusive supply relationship, providing us with good visibility over our future revenue potential.
UL Medicines, which primarily serves the hospitals sector, exited the year strongly following a softer first half. The business continues to consolidate its position as one of the leading suppliers of unlicensed imported medicines to the NHS. Following the result of the EU referendum in June 2016, the business has faced challenges relating to the impact of Sterling weakness on the cost of imported lines, however underlying hospital volumes are growing and the business has benefited from temporary supply opportunities following shortages of licensed products.
Medication Adherence division ('MA')
The MA division comprises Biodose Services, a homecare dispensary and delivery business, and Protomed, which provides medication management services through Biodose, its innovative multi-dose tray system. Divisional revenue increased by 125% to GBP25.4m (2016: GBP11.3m), driven by Biodose Services, which secured a number of new homecare contracts and saw continued growth in the Stork Fertility Service ('Stork'). The division delivered an adjusted EBITDA loss in the year of GBP0.2m (2016: GBP0.4m profit) overall, however the division was generating monthly profits as it exited the year.
The significant revenue base in the MA division is due to Biodose Services and the inherent characteristics of its homecare business model. The business model requires high-value medicines to be dispensed and delivered to patients at home, which results in high levels of revenue and costs and a low gross margin profile.
Trading in Protomed has been steady as the number of patients benefiting from the multi-dose tray system has remained similar to last year. The business has historically sought to commercialise Biodose Connect(TM), which is an extension of the multi-dose tray system. It allows carers and clinicians to remotely monitor a patient's adherence to their medication regime. It has become clear that Biodose Connect(TM) will require substantial further investment to establish it in the domiciliary care market, which is no longer a core area of focus for the Group.
Following our decision to focus our efforts on our core Specials and Niche businesses, we have commenced a strategic review of the MA division to conclude on its long-term fit within the Group.
Chris Rigg
Chief Executive Officer
2 May 2017
Chief Financial Officer's review
The cumulative financial impact of the Group's transition over the past financial year saw significant benefits to the underlying profitability run rate although this resulted in substantial non-recurring and non-operational charges arising from discontinued operations, impairment of product developments and costs incurred in implementing the simplified strategy. Underlying these results is a core Specials business model that is profitable and cash generative and a product development programme that is focused on the Group's unlicensed-to-licensed ('UL2L') strategy.
All figures in this section refer to continuing operations unless otherwise stated.
Group performance
The Group performance is summarised in the following measures:
-- Revenue increased by 28% to GBP88.8m (2016: GBP69.2m) -- Gross profit remained flat at GBP25.9m (2016: GBP25.9m) -- Gross margin declined to 29.2% (2016: 37.4%) -- Adjusted EBITDA declined to GBP10.1m (2016: GBP12.5m) -- Loss before tax of GBP10.9m (2016: GBP6.7m profit) -- Capitalised development expenditure of GBP4.0m was incurred (2016: GBP6.4m) -- Net debt reduced by almost half to GBP13.0m (2016: GBP24.6m)
Revenue
REVENUE BY DIVISION (GBPm) 2017 2016 ---------------------------- ----- ----- Specials 57.6 53.6 Niche Pharmaceuticals 5.8 4.3 Medication Adherence 25.4 11.3 ---------------------------- ----- ----- Group 88.8 69.2 ---------------------------- ----- -----
Group revenue grew by 28% to GBP88.8m (2016: GBP69.2m), primarily as a result of the revenue growth delivered in the Medication Adherence ('MA') division of GBP14.1m, representing 72% of the Group's total revenue increase of GBP19.6m. The balance of the Group's revenue growth of GBP5.5m was represented by the Specials division (GBP4.0m) and the Niche Pharmaceuticals division (GBP1.5m).
The Specials division delivered a strong performance during the year. It operates in a challenging market that is subject to regulated pricing across some of the division's product range. Despite these challenges, however, unlicensed medicines and special obtains volumes grew by 6% and demand for bespoke, aseptically-prepared specials also drove growth.
The Niche division licensed and launched Glycopyrronium Bromide Oral Solution 1mg/5ml ('Glyco') in the UK in August 2016, its first UL2L product with meaningful volume. Following the licensing of Glyco, other specials manufacturers of the medicine in the UK were required to cease supplying the market, making the Group the only licensed supplier at launch. The launch of Glyco is the main driver behind the Niche division's revenue growth of 35%, albeit this growth is on a low base.
The MA division exited the care home sector in the prior financial year to focus on pursuing alternative dispensing contract opportunities in the homecare sector. This revised strategy has been implemented successfully resulting in a number of important contracts with large pharmaceutical companies and NHS Trusts being secured during the financial year. The characteristic of this business is that the revenue recognised relates to the value of the medicines being dispensed, which generates a high level of revenue in this division and low levels of gross profit.
Gross profit
Despite the increase in Group revenue, gross profit was unchanged at GBP25.9m (2016: GBP25.9m) leading to a reduced gross profit margin of 29.2% (2016: 37.4%). This reduction is the result of the divisional revenue mix changing year-on-year and, in particular, the increase in lower margin homecare contracts in the MA division. The gross profit margin in the core Specials business remained stable.
Adjusted EBITDA
ADJUSTED EBITDA BY DIVISION 2017 2016 (GBPm) ----------------------------- ------ ------ Specials 10.1 10.7 Niche Pharmaceuticals 1.4 2.1 Medication Adherence (0.2) 0.4 Group costs (1.2) (0.7) ----------------------------- ------ ------ Group adjusted EBITDA 10.1 12.5 ----------------------------- ------ ------ RECONCILIATION TO OPERATING 2017 2016 (LOSS) PROFIT (GBPm) -------------------------------- ------- ------ Group adjusted EBITDA 10.1 12.5 Intangible amortisation and impairment (11.2) (0.7) Depreciation and impairment (1.6) (0.9) Impairment of investment (0.1) - Board restructuring (1.1) - Deferred consideration (Lamda) (2.0) (1.5) Share based payments (0.8) (0.1) Niche reorganisation (2.7) - Non-recurring costs (0.4) (0.4) Deal costs - (0.6) Divestment of Care Home operation - (0.8) -------------------------------- ------- ------ Group statutory operating (loss) profit (9.8) 7.5 -------------------------------- ------- ------
Adjusted EBITDA declined to GBP10.1m (2016: GBP12.5m) after adjusting for; depreciation, amortisation and impairments of GBP12.9m (2016: GBP1.6m); non-recurring or non-operational items totalling GBP6.2m
(2016: GBP3.3m); share based payments of GBP0.8m (2016: GBP0.1m); and excluding a loss on discontinued operations of GBP13.7m (2016: GBP0.3m). The contraction in adjusted EBITDA was evenly spread across all of the Group's divisions. Notable drivers include a year-on-year reduction in out-licensing revenue, an increased operating cost base in the first half and underperformance in certain areas of the business during a period of substantive change. Management actions taken during the second half of the financial year, particularly in the Niche division, have successfully addressed a number of these underperformance issues.
Non-recurring or non-operational items include a charge of GBP2.0m (2016: GBP1.5m) of deferred consideration for the Lamda acquisition, GBP1.1m (2016: GBPnil) for Board restructuring and a GBP2.7m loss
(2016: GBPnil) relating to the Niche reorganisation and discontinuation of products where management do not believe the Group has a strategic market advantage.
Discontinued operation
In July 2015 the Group acquired NuPharm Laboratories Limited ('NuPharm'), a small-scale batch-made specials manufacturer, which was intended to provide the Group with an internal capability to batch manufacture both unlicensed and licensed medicines. At the time of acquisition NuPharm was under MHRA manufacturing restrictions. Following acquisition the Group encountered further operational issues that needed to be addressed. Despite additional investment by the Group and the dedication of management time since its acquisition, NuPharm suffered trading losses.
The Board concluded that it would take unacceptable additional investment, further cash losses and management time to address the operational issues and that NuPharm was not capable of becoming earnings-enhancing. Consequently the Board took the decision to proceed with a closure plan for NuPharm and trading ceased in January 2017. Following an orderly closure process NuPharm was placed into administration on 26 April 2017. NuPharm's results are included along with the impairment of its associated intangible assets and closure costs within the loss from discontinued operations of GBP13.7m (2016: GBP0.3m) shown in the consolidated income statement as it represents a separate major line of business.
(Loss) profit before tax
RECONCILIATION TO (LOSS) PROFIT 2017 2016 FOR THE YEAR (GBPm) ------------------------------------- ------- ------ Group statutory operating (loss) profit (9.8) 7.5 Net financing expense (1.2) (0.9) Share of profit of equity-accounted investees, net of tax 0.1 0.1 Taxation 1.8 (0.8) ------------------------------------- ------- ------ (Loss) profit for the year - continuing operations (9.1) 5.9 ------------------------------------- ------- ------ Loss from discontinued operations (13.7) (0.3) (Loss) profit for the year (22.8) 5.6 ------------------------------------- ------- ------
The Group incurred a loss for the year of GBP22.8m (2016: GBP5.6m profit) comprising losses from discontinued operations of GBP13.7m (2016: GBP0.3m) and from continuing operations of GBP9.1m (2016: GBP5.9m profit). The statutory loss from continuing operations includes a number of non-recurring and non-operational costs associated with the transition to a more focused and simplified strategy that have been explained in the adjusted EBITDA section above.
(Loss) earnings per share - continuing operations
MOVEMENT IN BASIC (LOSS) EARNINGS 2017 2016
PER SHARE (Pence)
----------------------------------- ------- ------
Prior year earnings per share 4.7 1.3
Change due to:
(Loss) profit for the year (12.3) 8.9
Weighted average number of
shares in issue 0.9 (5.5)
Current year (loss) earnings
per share (6.7) 4.7
----------------------------------- ------- ------
The table bridges the movement in (loss) earnings per share year-on-year, showing the value of the movement that is attributable to the change in earnings and the value that is due to a change in the number of ordinary shares in issue.
Operating cash flow
The Group generated net cash inflows from continuing operating activities of GBP6.1m (2016: GBP7.9m) from a loss after tax for the year of GBP9.1m (2016: GBP5.9m profit). The loss after tax from continuing operations includes non-cash charges relating to depreciation, amortisation and impairment of GBP12.9m (2016: GBP1.6m). These non-cash charges explain why the Group's net cash inflows from operating activities in the current year are only GBP1.8m lower than the prior year. The other contributing factor is the improved working capital controls that have been implemented during the year. Net cash inflows from working capital during the year were GBP2.6m compared to GBP0.7m net outflows in 2016.
Discontinued operations incurred net cash outflows from operating activities of GBP2.2m (2016: GBP0.9m).
Investment
During the year the Group's capitalised development expenditure was GBP4.0m (2016: GBP6.4m) with development activities now focused on a clearly defined set of products aligned with the Group's strategy. At the same time all of the Group's development projects with the exception of one have been transferred from a portfolio of third-party contracted development organisations to Lamda to improve efficiency of execution and measurement of progress.
Net debt and banking facilities
NET DEBT (GBPm) 2017 2016 ------------------------------ ------ ------ Cash and cash equivalents (7.9) (4.2) Term loan 21.2 24.2 Revolving credit facility - 5.0 Unamortised loan issue costs (0.3) (0.4) Net debt 13.0 24.6 ------------------------------ ------ ------
Net debt was better than expected, reducing by 47% to GBP13.0m (2016: GBP24.6m), and comprised borrowings net of unamortised loan issue costs of GBP20.9m (2016: GBP28.8m) and cash and cash equivalents of GBP7.9m (2016: GBP4.2m). This was mainly due to the successful completion of a GBP15.0m (before expenses) equity fundraise in November 2016 and tighter working capital management across the year.
During the prior year, the Group agreed new banking facilities with RBS and Lloyds that increased overall debt facilities to GBP35.0m comprising a GBP25.0m term loan plus GBP10.0m revolving credit facility, which was undrawn at the year-end.
Dividend
The Board has decided not to declare a dividend in respect of the current financial year (2016: 1.5 pence per share).
Gerard Murray
Chief Financial Officer
2 May 2017
Appendix I - Non-GAAP measures
Metric Description Why we use it
----------- ------------------------------------------------------------ ----------------------------
Adjusted Adjusted EBITDA is statutory Adjusted EBITDA
EBITDA operating profit excluding: is profitability
* Depreciation and impairments of tangible non-current stated before the
assets; non-cash accounting
impact of depreciation,
amortisation, impairments,
* Amortisation and impairments of intangible share based payments,
non-current assets; and excludes the
potentially distorting
effects of non-recurring
* Items that management judge to be one-off or and non-operational
non-operational; and items. This is
the measure management
use internally
* Acquisition-related items. to assess the underlying
trading performance
of the business.
A reconciliation is
set out on page 10.
----------- ------------------------------------------------------------ ----------------------------
Adjusted Adjusted earnings per Adjusted earnings
earnings share is adjusted profit per share (and
per share after tax divided by the growth or contraction
the weighted average versus previous
number of ordinary shares periods) allows
in issue during the management to assess
financial year. the post-tax underlying
Adjusted profit after trading performance
tax is adjusted EBITDA: of the business
* Less depreciation and amortisation; in combination
with the impact
of capital structuring
* Less net financing expenses; actions on the
share base (e.g.
as a result of
* Plus the Group's share of profit of equity-accounted a share issue or
investees, net of tax; a share buyback
programme).
* Includes an accrued charge or credit for corporation
tax on taxable profits; and
* Includes movement in provisions for deferred tax.
All adjustments made
to adjusted EBITDA as
set out in the definition
above are net of tax
where applicable.
A reconciliation to
earnings per share is
provided in note 4 of
this announcement.
----------- ------------------------------------------------------------ ----------------------------
Net debt Net debt comprises: This represents
* The carrying value of all bank term loans; and the amount of the
Group's funding
structure that
* The carrying value of all drawn revolving credit is provided through
facilities and overdrafts. debt finance.
Less:
* Cash and cash equivalents; and
* Unamortised loan issue costs.
All amounts are closing
balances as at the relevant
balance sheet date.
A breakdown of net debt
is set out on page 12.
----------- ------------------------------------------------------------ ----------------------------
Consolidated Income Statement
for year ended 31 January 2017
Note 2017 2016
GBP000 GBP000
Continuing operations
Revenue 2 88,770 69,227
Cost of sales (62,846) (43,352)
-------- --------
Gross profit 25,924 25,875
Other operating income 16 204
Distribution expenses (2,600) (2,571)
Administrative expenses (33,186) (16,019)
-------- --------
Operating (loss) profit (9,846) 7,489
Financial expense (1,150) (902)
-------- --------
Net financing expense (1,150) (902)
Share of profit of equity-accounted
investees, net of tax 145 106
-------- --------
(Loss) profit before tax (10,851) 6,693
Taxation 1,790 (780)
-------- --------
(Loss) profit for the year from
continuing operations (9,061) 5,913
-------- --------
Discontinued operations
Loss for the year from discontinued
operations 3 (13,705) (317)
-------- --------
(Loss) profit for the year (22,766) 5,596
======== ========
Basic and diluted earnings per
share attributed to equity shareholders
of the Company
Basic (p): 4 (16.9) 4.5
Diluted (p): 4 (16.9) 4.3
Basic (p) - continuing operations
only: 4 (6.7) 4.7
Diluted (p) - continuing operations
only: 4 (6.7) 4.5
Basic (p) - discontinued operations
only: 4 (10.2) (0.2)
Diluted (p) - discontinued operations
only: 4 (10.2) (0.2)
======== ========
Consolidated Statement of Comprehensive Income
for year ended 31 January 2017
2017 2016
GBP000 GBP000
(Loss) profit for the year (22,766) 5,596
Other comprehensive income
Items that are or may be recycled
subsequently into profit or loss
Foreign exchange translation
differences 74 (3)
-------- ------
Other comprehensive income (loss)
for the year, net of income tax 74 (3)
-------- ------
Total comprehensive (loss) income
for the year (22,692) 5,593
======== ======
Attributable to:
Equity holders of the parent (22,692) 5,593
======== ======
Consolidated Balance Sheet
at 31 January 2017
Note 2017 2016
GBP000 GBP000
Non-current assets
Property, plant and equipment 4,211 5,967
Intangible assets 5 59,493 78,432
Investments - 105
-------- --------
63,704 84,504
-------- --------
Current assets
Inventories 3,985 4,887
Tax receivable 228 307
Trade and other receivables 14,965 13,410
Cash and cash equivalents 7,941 4,240
-------- --------
27,119 22,844
-------- --------
Total assets 90,823 107,348
======== ========
Current liabilities
Other interest-bearing
loans and borrowings (2,880) (7,880)
Trade and other payables (22,433) (18,943)
Provisions (572) (1,355)
(25,885) (28,178)
-------- --------
Non-current liabilities
Other interest-bearing
loans and borrowings (18,080) (20,959)
Other payables - (19)
Provisions - (439)
Deferred tax liabilities (244) (2,244)
-------- --------
(18,324) (23,661)
-------- --------
Total liabilities (44,209) (51,839)
======== ========
Net assets 2 46,614 55,509
======== ========
Consolidated Balance Sheet (continued)
at 31 January 2017
2017 2016
GBP000 GBP000
Equity attributable
to equity holders
of the parent
Share capital 16,912 12,500
Share premium 74,799 64,940
Consolidation reserve (9,752) (9,752)
Translation reserve 116 42
Other reserve (21,726) (21,726)
ESOP own share reserve (484) (484)
Merger reserve 8,742 8,742
Retained earnings (21,993) 1,247
-------- --------
Total equity 46,614 55,509
======== ========
These financial statements were approved by the Board of Directors on 2 May 2017 and were signed on its behalf by:
G T Murray
Director
Company registered number: 9269818
Consolidated Statement of Changes in Equity
ESOP
own
Share Share Consolidation Translation Other share Merger Retained Total
capital premium reserve reserve reserve reserve reserve earnings equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Balance at 1
February
2016 12,500 64,940 (9,752) 42 (21,726) (484) 8,742 1,247 55,509
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Total
comprehensive
income for the
year
Loss for the year - - - - - - - (22,766) (22,766)
Other
comprehensive
income - - - 74 - - - - 74
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Total
comprehensive
income for the
year - - - 74 - - - (22,766) (22,692)
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Transactions with
owners,
recorded directly
in
equity
Issue of ordinary
shares 4,412 10,588 - - - - - - 15,000
Issue costs
charged
against share
premium - (729) - - - - - - (729)
Contributions by
and
distributions to
owners - - - - - - - (1,250) (1,250)
Equity-settled
share
based payment
transactions - - - - - - - 776 776
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Total
contributions
by and
distributions
to
owners 4,412 9,859 - - - - - (474) 13,797
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Total
transactions
with
owners 4,412 9,859 - - - - - (474) 13,797
-------- -------- --------------- ----------- -------- -------- -------- --------- --------
Balance at 31
January
2017 16,912 74,799 (9,752) 116 (21,726) (484) 8,742 (21,993) 46,614
======== ======== =============== =========== ======== ======== ======== ========= ========
Consolidated Statement of Changes in Equity (continued)
ESOP
own
Share Share Consolidation Translation Other share Merger Retained Total
capital premium reserve reserve reserve reserve reserve earnings equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Balance at 1
February
2015 12,500 64,940 (9,752) 45 (21,726) (484) 8,742 (3,545) 50,720
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Total
comprehensive
income for the
year
Profit for the
year - - - - - - - 5,596 5,596
Other
comprehensive
loss - - - (3) - - - - (3)
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Total
comprehensive
income for the
year - - - (3) - - - 5,596 5,593
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Transactions with
owners, recorded
directly in equity
Contributions by
and distributions
to owners - - - - - - - (937) (937)
Equity-settled
share
based payment
transactions - - - - - - - 133 133
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Total
contributions
by and
distributions
to owners - - - - - - - (804) (804)
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Total transactions
with owners - - - - - - - (804) (804)
-------- -------- --------------- ----------- -------- -------- -------- --------- -------
Balance at 31
January
2016 12,500 64,940 (9,752) 42 (21,726) (484) 8,742 1,247 55,509
======== ======== =============== =========== ======== ======== ======== ========= =======
Consolidated Cash Flow Statement
for year ended 31 January 2017
Note 2017 2016
GBP000 GBP000
Cash flows from operating
activities
(Loss) profit for the
year from continuing
operations (9,061) 5,913
Adjustments for:
Depreciation, amortisation
and impairment 12,956 1,631
Financial expense 1,150 902
Share of profit of
equity-accounted investees (145) (106)
Equity settled share-based
payment expenses 776 133
Taxation (1,790) 780
------- --------
3,886 9,253
Increase in trade and
other receivables (1,739) (920)
Decrease (increase)
in inventories 651 (575)
Increase in trade and
other payables 3,647 1,241
Increase (decrease)
in provisions 44 (501)
------- --------
6,489 8,498
Interest paid (929) (720)
Tax received 546 83
------- --------
Net cash inflow from continuing
operating activities 6,106 7,861
Net cash outflow from operating
activities in discontinued operations (2,222) (884)
------- --------
Net cash inflow from
operating activities 3,884 6,977
------- --------
Cash flows from investing
activities
Acquisition of property,
plant and equipment (719) (1,845)
Acquisition of subsidiaries,
net of cash acquired - (3,285)
Acquisition of investment - (105)
Capitalised development
expenditure 5 (4,035) (6,355)
Acquisition of other
intangible assets 5 (212) (287)
------- --------
Net cash outflow from investing
activities in continuing operations (4,966) (11,877)
Net cash outflow from investing
activities in discontinued operations (238) (9,075)
------- --------
Net cash outflow from investing
activities (5,204) (20,952)
------- --------
Cash flows from financing
activities
Proceeds from the issue of share
capital (net of expenses) 14,271 -
Proceeds from new loan - 29,520
Repayment of borrowings (8,000) (15,754)
Dividends paid (1,250) (937)
Net cash inflow from financing
activities in continuing operations 5,021 12,829
Net cash outflow from financing
activities in discontinued operations - (487)
------- --------
Net cash inflow from financing
activities 5,021 12,342
------- --------
Net increase (decrease) in cash
and cash equivalents 3,701 (1,633)
Cash and cash equivalents
at start of year 4,240 5,873
------- --------
Cash and cash equivalents
at year end 7,941 4,240
======= ========
Notes
1 Basis of preparation and status of financial information
The financial information set out above has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards as adopted by the EU (Adopted IFRSs).
The financial information set out above does not constitute the Group's statutory accounts for the years ended 31 January 2017 or 2016. Statutory accounts for 2016 have been delivered to the Registrar of Companies, and those for 2017 will be delivered in due course. The auditor has reported on those accounts; their reports were (i) unqualified, (ii) did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report (iii) did not contain a statement under s498 (2) or (3) of the Companies Act 2006.
These results were approved by the Board of Directors on 2 May 2017.
2 Segmental reporting
The following analysis by segment is presented in accordance with IFRS 8 on the basis of those segments whose operating results are regularly reviewed by the Board (the Chief Operating Decision Maker as defined by IFRS 8) to assess performance and make strategic decisions about allocation of resources.
The sectors distinguished as operating segments are Specials, Niche Pharmaceuticals and Medication Adherence. A short description of these sectors is as follows:
-- Specials - Manufacture, source and supply special medicines to pharmacies, pharmaceutical wholesalers, hospitals (NHS and private) and other specials suppliers throughout the UK and overseas.
-- Niche Pharmaceuticals (Niche) - develop and supply niche pharmaceuticals, provide development and regulatory services and out-license products and dossiers to third parties in the UK and overseas.
-- Medication Adherence (MA) - provide products and services designed to enhance adherence to medication regimes.
These operating segments have separate management teams and offer different products and services and are considered as reportable segments. The segment results, as reported to the Board, are calculated under the principles of IFRS. Performance is measured on the basis of Adjusted EBITDA which comprises the segment result before non-cash items (amortisation, depreciation and share based payments) and other items that are excluded when the Board assess performance. A reconciliation between Adjusted EBITDA and profit (loss) before tax is included in the tables below:
The results shown below are from continuing operations only.
31 January 2017
Specials Niche MA Total
GBP000 GBP000 GBP000 GBP000
Result and reconciliation
to loss before tax
Total revenue 62,477 7,862 25,496 95,835
Intersegmental (4,910) (2,077) (78) (7,065)
-------- -------- -------- ---------
Revenue 57,567 5,785 25,418 88,770
======== ======== ======== =========
Segment Adjusted
EBITDA 10,067 1,434 (208) 11,293
Group cost centres (1,164)
---------
Group Adjusted
EBITDA 10,129
Intangible amortisation
and impairment (11,195)
Depreciation and
impairment (1,656)
Impairment of investment (105)
Board restructuring (1,085)
Deferred consideration accounted
for as remuneration (Lamda) (1,977)
Share based payments (776)
Niche reorganisation (2,666)
Non-recurring costs (515)
---------
Operating loss (9,846)
Financial expense (1,150)
Share of profit of
jointly controlled
entities 145
Loss before tax from continuing
operations (10,851)
=========
NET ASSETS
Segment assets 93,035 16,678 8,671 118,384
Segment liabilities (56,801) (24,427) (23,460) (104,688)
-------- -------- -------- ---------
Segment net assets
(liabilities) 36,234 (7,749) (14,789) 13,696
Unallocated
net assets 32,918
---------
Total net assets 46,614
=========
Depreciation, amortisation
and impairment 1,654 8,319 2,983 12,956
Capital expenditure 121 464 184 769
Capitalised development,
patent and software costs 233 3,685 329 4,247
======== ======== ======== =========
Unallocated net assets include cash and cash equivalents (GBP1.6m), trade and other payables (GBP1.1m), bank term loans (GBP21.0m) and net intra-group loan receivables (GBP53.4m).
31 January 2016
Specials Niche MA Total
GBP000 GBP000 GBP000 GBP000
Result and reconciliation
to profit before tax
Total revenue 58,770 6,480 11,508 76,758
Intersegmental (5,142) (2,226) (163) (7,531)
-------- -------- -------- --------
Revenue 53,628 4,254 11,345 69,227
======== ======== ======== ========
Segment Adjusted
EBITDA 10,723 2,127 405 13,255
Group cost centres (757)
--------
Group Adjusted
EBITDA 12,498
Intangible amortisation
and impairment (723)
Depreciation (908)
Deal costs (625)
Deferred consideration accounted
for as remuneration (Lamda) (1,461)
Share based payments (133)
Divestment of Care
Home operation (796)
Non-recurring costs (363)
--------
Operating profit 7,489
Financial expense (902)
Share of profit of
jointly controlled
entities 106
--------
Profit before taxation
from continuing operations 6,693
========
NET ASSETS
Segment assets 107,708 18,543 9,847 136,098
Segment liabilities (56,378) (16,473) (18,648) (91,499)
-------- -------- -------- ----------
Segment net assets
(liabilities) 51,330 2,070 (8,801) 44,599
Unallocated net
assets 10,910
----------
Total net assets 55,509
==========
Depreciation, amortisation
and impairment 902 329 400 1,631
Capital expenditure 1,157 392 296 1,845
Capitalised development,
patent and software
costs 232 5,615 795 6,642
======== ======== ======== ==========
Unallocated net assets includes trade and other payables (GBP0.4m), bank term loan (GBP28.8m) and net intra-group loan receivables (GBP40.1m).
In both years revenue is generated almost entirely in the UK. In the year ended 31 January 2017 one (2016: one) customer accounted for 23% (2016: 24%) of Group revenue.
3 Discontinued operations
The Group's discontinued operation, NuPharm Laboratories Limited, made a loss of GBP13.7m (2016: GBP0.3m) after tax during the year. These losses have been classified as discontinued in the current year, with prior year restatement, as NuPharm Laboratories Limited represents a separate major line of business.
2017 2016
GBP000 GBP000
Revenue 1,303 763
Cost of sales (2,126) (402)
-------- -------
Gross (loss)
profit (823) 361
Other operating
income 70 -
Distribution
expenses (31) (23)
Administrative
expenses (543) (642)
Intangible amortisation (209) (138)
Impairment of goodwill
and other intangibles (12,049) -
Depreciation (200) (83)
Impairment of tangible
fixed assets (590) -
-------- -------
Operating loss (14,375) (525)
Financial expense (7) (3)
-------- -------
Loss before tax from
discontinued operation (14,382) (528)
Taxation
Current tax credit 136 186
Deferred tax
credit 541 25
-------- -------
Loss for the year from
discontinued operations (13,705) (317)
======== =======
2017 2016
GBP000 GBP000
The major classes of assets
and liabilities directly
attributable to the discontinued
operation are:
Non-current assets - 12,810
Inventories - 251
Trade and other
receivables 25 208
Cash and cash
equivalents 5 35
Trade and other
payables (377) (637)
Provisions (459) (1,605)
Tax liabilities - (599)
======== =======
4 Earnings per share
Continuing Total Continuing Total
operations Group operations Group
2017 2017 2016 2016
GBP000 GBP000 GBP000 GBP000
(Loss) profit attributable to
equity shareholders of the parent (9,061) (22,766) 5,913 5,596
=========== ======== =========== =======
2017 2016
Number Number
('000) ('000)
Basic weighted average number
of shares 134,764 125,000
Dilutive potential ordinary
shares - 6,117
----------- -------
Diluted weighted average number
of shares 134,764 131,117
=========== =========
Pence Pence
Basic (loss)
earnings per
share (16.9) 4.5
Diluted (loss) earnings
per share (16.9) 4.3
Basic (loss) earnings per share
- continuing operations (6.7) 4.7
Diluted (loss) earnings per
share - continuing operations (6.7) 4.5
Basic loss per share - discontinued
operations (10.2) (0.2)
Diluted loss per share - discontinued
operations (10.2) (0.2)
Basic weighted average number of shares include those shares in the EBT to which the beneficiaries are unconditionally entitled.
The dilutive potential shares relate to the share options. There were no potentially dilutive shares or other instrument that have been excluded from Diluted EPS because they are antidilutive.
Adjusted EPS 2017 2016
GBP000 GBP000
(Loss) profit
after tax (9,061) 5,913
Add:
Impairment of intangible
assets 9,403 -
Impairment of
investment 105 -
Board restructuring 1,085 -
Deal costs - 625
Deferred consideration
accounted for as remuneration
(Lamda) 1,977 1,461
Share based payments 776 133
Divestment of Care Home
operation - 796
Niche reorganisation 2,666 -
Non-recurring costs 515 363
Finance costs 103 143
Less: tax associated with
adjustments (874) (325)
------- -------
Adjusted profit after
tax 6,695 9,109
======= =======
The adjusted EPS, based on the adjusted earnings above for the year from continuing operations and weighted average number of shares in issue of 134,764,000 (2016: 125,000,000) is 5.0 pence (2016: 7.3 pence).
The adjusted diluted earnings per share based on the adjusted earnings from continuing operations above and a weighted average number of shares of 134,764,000 (2016: 131,117,000) is 5.0 pence (2016: 6.9 pence).
5 Intangible assets
Software Patents Customer
development Development and relationship
costs trade-marks Goodwill Total
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
Cost
Balance at
1 February
2015 42 5,363 252 1,728 60,319 67,704
Internal developments - 6,355 - - - 6,355
External purchases 240 - 47 - - 287
Acquisitions
through business
combinations - - - 2,787 12,340 15,127
Balance at
31 January
2016 282 11,718 299 4,515 72,659 89,473
============ =========== ============ ============= ======== ========
Balance at
1 February
2016 282 11,718 299 4,515 72,659 89,473
Internal developments - 4,035 - - - 4,035
External purchases 72 - 140 - - 212
Reclassified
from tangibles 519 - - - - 519
Transfers (142) 142 - - - -
------------ ----------- ------------ ------------- -------- --------
Balance at
31 January
2017 731 15,895 439 4,515 72,659 94,239
============ =========== ============ ============= ======== ========
Amortisation
and impairment
Balance at
1 February
2015 - 128 74 519 9,459 10,180
Amortisation
for the year 2 441 26 312 - 781
Impairment - 80 - - - 80
Balance at
31 January
2016 2 649 100 831 9,459 11,041
============ =========== ============ ============= ======== ========
Balance at
1 February
2016 2 649 100 831 9,459 11,041
Amortisation
for the year 46 1,544 29 382 - 2,001
Impairment - 7,910 249 2,439 10,854 21,452
Reclassified
from tangibles 252 - - - - 252
------------ ----------- ------------ ------------- -------- --------
Balance at
31 January
2017 300 10,103 378 3,652 20,313 34,746
============ =========== ============ ============= ======== ========
Net book value
At 31 January
2016 280 11,069 199 3,684 63,200 78,432
At 31 January
2017 431 5,792 61 863 52,346 59,493
============ =========== ============ ============= ======== ========
Impairment and amortisation
The impairment and amortisation charges are recognised in the following line items in the consolidated income statement:
Impairment Amortisation
2017 2016 2017 2016
GBP000 GBP000 GBP000 GBP000
Administrative
expenses 9,403 80 1,792 781
Discontinued
operations 12,049 - 209 -
-------------- -------------- ---------------- ---------------
21,452 80 2,001 781
============== ============== ================ ===============
An impairment charge of GBP21,452,000 (2016: GBP80,000) has been recognised in the year arising from the decisions to discontinue NuPharm operations GBP12,049,000 (2016: GBPnil), not progress the development of certain medicines GBP7,210,000 (2016: GBP80,000) and the write down of goodwill and other intangible assets in respect of Protomed Limited GBP2,193,000 (2016: GBPnil) due to uncertainty over the level of future profits.
Impairment testing
Goodwill and indefinite life intangible assets considered significant in comparison to the Group's total carrying amount of such assets have been allocated to cash generating units or groups of cash generating units as follows:
Goodwill 2017 2016
GBP000 GBP000
Quantum Pharmaceutical
Limited 37,703 37,703
U L Medicines
Limited 9,647 9,647
Colonis Pharma
Limited and
Lamda 3,155 3,155
Total Medication Management
Services Limited ("TOMMS") 1,841 1,841
Protomed Limited - 1,245
NuPharm Group
Limited - 9,609
------ ------
52,346 63,200
====== ======
The recoverable amount of the goodwill allocated to the above cash generating units has been calculated with reference to their value in use. The key assumptions of this calculation are shown below:
2017 2016
Period on which management 3 years 3 years
approved forecasts are based
Growth rate applied beyond
approved forecast period 0% 0%
Discount rate 8-10% 10%
Management have assumed 0% growth beyond the forecast period. The forecast period is based on a three year business model approved by the Board. The key assumption in those forecasts is revenue. Forecasts for the more established businesses are based on historical growth trends. For the less mature businesses, forecast revenues are based on management's assessment of market trends and the impact of the Group's growth initiatives. In respect of Colonis and Lamda, forecast revenue is based on estimated revenues for each product in development, which in turn is based on estimated market size and the Group's likely market share.
The recoverable amount of these cash generating units has been calculated with reference to their value in use. Management have used a pre-tax discount rate ranging from 8% to 10% that reflects current market assessments for the time value of money and the risks associated with the CGU. A discount rate of 8% has been applied to the core mature business units within the Group, namely Quantum Pharmaceutical Limited and UL Medicines Limited, with a 10% discount rate applied to the less mature business units and revenue streams, namely TOMMS, 'Colonis Pharma Limited and Lamda'. A further analysis would be done if this suggested that the impairment assessment was sensitive to the discount rate. Management has performed sensitivity analysis on all the impairment calculations by increasing the pre-tax discount rate by 5% to 13% and 15% respectively and sensitising revenue by 5% and no impairment would arise in any period.
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR UUARRBOAVRUR
(END) Dow Jones Newswires
May 03, 2017 02:00 ET (06:00 GMT)
1 Year Quantum Phar. Chart |
1 Month Quantum Phar. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
